Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D03VUU
|
||||
Former ID |
DNC010210
|
||||
Drug Name |
2-(9,10-dihydroanthracen-9-yl)-N-methylethanamine
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [530331] | ||
Structure |
Download2D MOL |
||||
Formula |
C17H19N
|
||||
Canonical SMILES |
CNCCC1C2=CC=CC=C2CC3=CC=CC=C13
|
||||
InChI |
1S/C17H19N/c1-18-11-10-17-15-8-4-2-6-13(15)12-14-7-3-5-9-16(14)17/h2-9,17-18H,10-12H2,1H3
|
||||
InChIKey |
PVWQFOKNAQZORV-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Histamine H1 receptor | Target Info | Inhibitor | [530331] | |
5-hydroxytryptamine 2A receptor | Target Info | Inhibitor | [530331] | ||
WikiPathways | Monoamine GPCRs | ||||
GPCRs, Class A Rhodopsin-like | |||||
IL-4 Signaling Pathway | |||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling | |||||
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
SIDS Susceptibility Pathways | |||||
GPCR downstream signaling | |||||
GPCRs, Other | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.